Drug Profile

ART 6043

Alternative Names: ART-6043

Latest Information Update: 26 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Artios Pharma
Class Antineoplastics; Small molecules
Mechanism of Action DNA polymerase theta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours

Most Recent Events

17 Nov 2025 Artios Pharma plans a phase II trial for HER2-negative breast cancer (Metastatic disease) in November 2025
17 Oct 2025 Efficacy, adverse events, pharmacodynamics, drug interaction and pharmacokinetics data from a phase I/IIa trial in Solid tumours released by Artios Pharma
17 Oct 2025 Artios Pharma plans a phase II trial for Solid tumours (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com